Deciphera Pharmaceuticals, Inc. Net Income (Loss) Available to Common Stockholders, Basic
Deciphera Pharmaceuticals, Inc. reported Net Income (Loss) Available to Common Stockholders, Basic of -$194.94 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-07.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2024-02-07
- Deciphera Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for fiscal 2023 was -$194.94M.
- Deciphera Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for fiscal 2022 was -$178.93M.
- Deciphera Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for fiscal 2021 was -$299.96M.
- Deciphera Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for fiscal 2020 was -$266.49M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|
| 2023-12-31 | -$194.94M 10-K · filed 2024-02-07 |
| 2022-12-31 | -$178.93M 10-K · filed 2024-02-07 |
| 2021-12-31 | -$299.96M 10-K · filed 2024-02-07 |
| 2020-12-31 | -$266.49M 10-K · filed 2023-02-07 |
| 2019-12-31 | -$192.26M 10-K · filed 2022-02-08 |
| 2018-12-31 | -$99.85M 10-K · filed 2021-02-09 |
| 2017-12-31 | -$50.28M 10-K · filed 2020-03-09 |
| 2016-12-31 | -$25.94M 10-K · filed 2019-03-14 |
| 2015-12-31 | -$19.82M 10-K · filed 2018-03-28 |